Tracy E Madsen1,2, Olivia W Cummings1, Felipe De Los Rios La Rosa3,4, Jane C Khoury5,6, Kathleen Alwell4, Daniel Woo4,7, Simona Ferioli4,7, Sharyl Martini8, Opeolu Adeoye9, Pooja Khatri4,7, Matthew L Flaherty4,7, Jason Mackey10, Eva A Mistry4,7, Stacie L Demel4,7, Elisheva Coleman11, Adam S Jasne12, Sabreena J Slavin13, Kyle Walsh4,7, Michael Star14, Joseph P Broderick4,7, Brett M Kissela4,7, Dawn O Kleindorfer4,7. 1. Department of Emergency Medicine, Alpert Medical School of Brown University, Providence, RI (T.E.M., O.W.C.). 2. Department of Epidemiology, Brown University School of Public Health, Providence, RI (T.E.M.). 3. Miami Neuroscience Institute, Baptist Health South Florida (F.D.L.R.L.R.). 4. Department of Neurology and Rehabilitation Medicine (F.D.L.R.L.R., K.A., D.W., S.F., P.K., M.L.F., E.A.M., S.L.D., K.W., J.P.B., B.M.K., D.O.K.), University of Cincinnati College of Medicine, OH. 5. Department of Pediatrics (J.C.K.), University of Cincinnati College of Medicine, OH. 6. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, OH (J.C.K.). 7. UC Gardner Neuroscience Institute, Cincinnati, OH (D.W., S.F., P.K., M.L.F., E.A.M., S.L.D., K.W., J.P.B., B.M.K., D.O.K.). 8. Neurology Program, Veterans Health Administration and Department of Neurology, Baylor College of Medicine, Houston, TX (S.M.). 9. Department of Emergency Medicine, Washington University, St. Louis, MO (O.A.). 10. Department of Neurology, Indiana University School of Medicine, Indianapolis (J.M.). 11. Department of Neurology, University of Chicago, IL (E.C.). 12. Department of Neurology, Yale School of Medicine, New Haven, CT (A.S.J.). 13. University of Kansas Medical Center (S.J.S.). 14. Soroka Medical Center, Beersheva, Israel (M.S.).
Abstract
BACKGROUND: Though stroke risk factors such as substance use may vary with age, less is known about trends in substance use over time or about performance of toxicology screens in young adults with stroke. METHODS: Using the Greater Cincinnati Northern Kentucky Stroke Study, a population-based study in a 5-county region comprising 1.3 million people, we reported the frequency of documented substance use (cocaine/marijuana/opiates/other) obtained from electronic medical record review, overall and by race/gender subgroups among physician-adjudicated stroke events (ischemic and hemorrhagic) in adults 20 to 54 years of age. Secondary analyses included heavy alcohol use and cigarette smoking. Data were reported for 5 one-year periods spanning 22 years (1993/1994-2015), and trends over time were tested. For 2015, to evaluate factors associated with performance of toxicology screens, multiple logistic regression was performed. RESULTS: Overall, 2152 strokes were included: 74.5% were ischemic, mean age was 45.7±7.6, 50.0% were women, and 35.9% were Black. Substance use was documented in 4.4%, 10.4%, 19.2%, 24.0%, and 28.8% of cases in 1993/1994, 1999, 2005, 2010, and 2015, respectively (Ptrend<0.001). Between 1993/1994 and 2015, documented substance use increased in all demographic subgroups. Adjusting for gender, comorbidities, and National Institutes of Health Stroke Scale, predictors of toxicology screens included Black race (adjusted odds ratio, 1.58 [95% CI, 1.02-2.45]), younger age (adjusted odds ratio, 0.70 [95% CI, 0.53-0.91], per 10 years), current smoking (adjusted odds ratio, 1.62 [95% CI, 1.06-2.46]), and treatment at an academic hospital (adjusted odds ratio, 1.80 [95% CI, 1.14-2.84]). After adding chart-reported substance use to the model, only chart-reported substance abuse and age were significant. CONCLUSIONS: In a population-based study of young adults with stroke, documented substance use increased over time, and documentation of substance use was higher among Black compared with White individuals. Further work is needed to confirm race-based disparities and trends in substance use given the potential for bias in screening and documentation. Findings suggest a need for more standardized toxicology screening.
BACKGROUND: Though stroke risk factors such as substance use may vary with age, less is known about trends in substance use over time or about performance of toxicology screens in young adults with stroke. METHODS: Using the Greater Cincinnati Northern Kentucky Stroke Study, a population-based study in a 5-county region comprising 1.3 million people, we reported the frequency of documented substance use (cocaine/marijuana/opiates/other) obtained from electronic medical record review, overall and by race/gender subgroups among physician-adjudicated stroke events (ischemic and hemorrhagic) in adults 20 to 54 years of age. Secondary analyses included heavy alcohol use and cigarette smoking. Data were reported for 5 one-year periods spanning 22 years (1993/1994-2015), and trends over time were tested. For 2015, to evaluate factors associated with performance of toxicology screens, multiple logistic regression was performed. RESULTS: Overall, 2152 strokes were included: 74.5% were ischemic, mean age was 45.7±7.6, 50.0% were women, and 35.9% were Black. Substance use was documented in 4.4%, 10.4%, 19.2%, 24.0%, and 28.8% of cases in 1993/1994, 1999, 2005, 2010, and 2015, respectively (Ptrend<0.001). Between 1993/1994 and 2015, documented substance use increased in all demographic subgroups. Adjusting for gender, comorbidities, and National Institutes of Health Stroke Scale, predictors of toxicology screens included Black race (adjusted odds ratio, 1.58 [95% CI, 1.02-2.45]), younger age (adjusted odds ratio, 0.70 [95% CI, 0.53-0.91], per 10 years), current smoking (adjusted odds ratio, 1.62 [95% CI, 1.06-2.46]), and treatment at an academic hospital (adjusted odds ratio, 1.80 [95% CI, 1.14-2.84]). After adding chart-reported substance use to the model, only chart-reported substance abuse and age were significant. CONCLUSIONS: In a population-based study of young adults with stroke, documented substance use increased over time, and documentation of substance use was higher among Black compared with White individuals. Further work is needed to confirm race-based disparities and trends in substance use given the potential for bias in screening and documentation. Findings suggest a need for more standardized toxicology screening.
Authors: Dawn O Kleindorfer; Jane Khoury; Charles J Moomaw; Kathleen Alwell; Daniel Woo; Matthew L Flaherty; Pooja Khatri; Opeolu Adeoye; Simona Ferioli; Joseph P Broderick; Brett M Kissela Journal: Stroke Date: 2010-05-20 Impact factor: 7.914
Authors: Felipe de los Ríos; Dawn O Kleindorfer; Jane Khoury; Joseph P Broderick; Charles J Moomaw; Opeolu Adeoye; Matthew L Flaherty; Pooja Khatri; Daniel Woo; Kathleen Alwell; Jane Eilerman; Simona Ferioli; Brett M Kissela Journal: Stroke Date: 2012-11-15 Impact factor: 7.914
Authors: J Broderick; T Brott; R Kothari; R Miller; J Khoury; A Pancioli; J Gebel; D Mills; L Minneci; R Shukla Journal: Stroke Date: 1998-02 Impact factor: 7.914
Authors: Scott J Moeller; David S Fink; Misato Gbedemah; Deborah S Hasin; Sandro Galea; Michael J Zvolensky; Renee D Goodwin Journal: J Clin Psychiatry Date: 2018 May/Jun Impact factor: 4.384
Authors: Loes C A Rutten-Jacobs; Renate M Arntz; Noortje A M Maaijwee; Henny C Schoonderwaldt; Lucille D Dorresteijn; Ewoud J van Dijk; Frank-Erik de Leeuw Journal: JAMA Date: 2013-03-20 Impact factor: 56.272
Authors: Dawn O Kleindorfer; Amytis Towfighi; Seemant Chaturvedi; Kevin M Cockroft; Jose Gutierrez; Debbie Lombardi-Hill; Hooman Kamel; Walter N Kernan; Steven J Kittner; Enrique C Leira; Olive Lennon; James F Meschia; Thanh N Nguyen; Peter M Pollak; Pasquale Santangeli; Anjail Z Sharrief; Sidney C Smith; Tanya N Turan; Linda S Williams Journal: Stroke Date: 2021-05-24 Impact factor: 7.914